CA
NZ
UK
AU
IND
US
AbCellera Biologics (NASDAQ: ABCL) announced that collaborations with Jazz Pharmaceuticals and Vertex Pharmaceuticals have delivered $84 million and $28 million in upfront payments respectively, pushing total upfront cash received to over $100 million. The influx arrives as the company reported a $55.4 million net …
The company logged a $21.4 million net loss, equal to $1.99 per diluted share, but retained $118.2 million in cash and short‑term investments, enough to cover expenses through the second half of 2027.
The report marks a notable turnaround as total revenue grew by 7% year-over-year to $1.49 billion, up from $1.39 billion during the same period last year. This positive performance is reflective of better-than-expected operational metrics, highlighting the efficacy of Agilon's strategic initiatives amid current …
Jin Medical International Ltd. (NASDAQ: ZJYL) shares closed up 14% at $2.21, after surging more than 63% after hours, as investors reacted to margin improvement despite a decline in reported revenue.
Enveric Biosciences (NASDAQ: ENVB) released fresh GloSensor cAMP assay findings consistent with previous BRET data, further validating the non-hallucinogenic preclinical profile of its EB-003 candidate.
Precigen (NASDAQ: PGEN) reported Q2 FY2026 revenue growth to $54.98 million from $0.86 million a year earlier, as the firm swung to net income of $20.07 million.
BriaCell Therapeutics (NASDAQ: BCTX) announced that the FDA has cleared the IND application for Bria-PROS+, its novel personalized off-the-shelf immunotherapy candidate.
A cluster of biopharmaceutical and specialty healthcare names moved on a wide range of corporate news in a single session, spanning accelerating commercial drug launches, a Nasdaq-compliance reverse stock split, an analyst price target increase, mixed quarterly results, and both preclinical and regulatory pipeline …
LeMaitre Vascular (NASDAQ: LMAT) shares closed down 25% at $79 despite the company reporting Q2 FY2026 net sales growth of 10% to $70.4 million, with EPS climbing 23% to $0.74.
Jupiter Neurosciences (NASDAQ: JUNS) shares closed down 26% at $0.08 after the company finalized a 1-for-75 reverse stock split scheduled for August 6, 2026, with adjusted trading commencing the following day under its existing ticker.
Please wait processing your request...